Knight Therapeutics Inc.
KHTRF
$4.32
-$0.05-1.19%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.73% | 26.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.73% | 26.44% | |||
| Cost of Revenue | 5.61% | 21.89% | |||
| Gross Profit | 25.05% | 33.38% | |||
| SG&A Expenses | -1.03% | 24.94% | |||
| Depreciation & Amortization | 44.59% | 17.49% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.39% | 23.03% | |||
| Operating Income | 117.69% | 31.27% | |||
| Income Before Tax | 87.66% | -3,958.42% | |||
| Income Tax Expenses | 163.00% | -19.94% | |||
| Earnings from Continuing Operations | 69.83% | -699.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.83% | -699.19% | |||
| EBIT | 117.69% | 31.27% | |||
| EBITDA | 118.41% | 45.28% | |||
| EPS Basic | 69.87% | -698.69% | |||
| Normalized Basic EPS | 120.90% | -48,700.00% | |||
| EPS Diluted | 69.15% | -776.26% | |||
| Normalized Diluted EPS | 120.90% | -48,700.00% | |||
| Average Basic Shares Outstanding | 0.03% | -0.01% | |||
| Average Diluted Shares Outstanding | 0.03% | -0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||